Purespring Therapeutics

Check out Purespring’s Emerging Company Profile, published last week by BioCentury Inc. Inc!   Our CEO, Julian Hanak, and CMO, Fredrik Erlandsson, enjoyed the opportunity to sit down with Danielle Golovin, Ph.D. and discuss our novel #GeneTherapy platform, the first to selectively target the #podocyte for the treatment of chronic #KidneyDiseases and recent #pipeline progress.   Read the full company profile here to learn more: https://lnkd.in/ey9ppRWS   #Profile #Biotech #Innovation #CellAndGeneTherapy

Last month, Kidney Research UK (KRUK) held their annual Research Showcase, celebrating the recent #research milestones they have funded that have the potential to transform the lives of patients living with #KidneyDiseases.   Presentations from KRUK’s Chief Executive, Sandra Currie, and Executive Director of Research and Policy, Dr Aisling McMahon, were accompanied by a moving speech from Charlie, a 14-year-old kidney activist, who shared his diagnosis and treatment journey with nephronophthisis, a genetic condition that causes scarring and cysts on the kidneys.   As a company dedicated to leading a revolution in the treatment of #KidneyDisease, events like this further inspire us to bring disease-modifying treatments to patients to stop kidney disease in its tracks. Thank you to KRUK and the Royal College of Surgeons for hosting!   #GeneTherapy #Event #Biotech

Purespring CEO, Julian Hanak, and CMO, Fredrik Erlandsson, discuss #DrugDevelopment for renal diseases in an exciting new BioCentury Inc. piece by Lauren Martz, which explores the changing dynamics behind #pipeline growth, funding and M&A activity in the kidney disease space. In the article, Julian and Fredrik discuss recent positive shifts in the #research and regulatory environments that have made renal drug development much easier and more likely to succeed. They also touch on the potential of precision medicine, such as our podocyte-targeting AAV #GeneTherapy approach, to bring novel therapeutic options and #innovation to a broad range of kidney conditions. To read the full article: https://lnkd.in/dJSMpknj #Biotech #CellAndGeneTherapy

Today Sam Illingworth, Head of Translational Research at Purespring, will be in Stockholm, Sweden to present preclinical data at the 61st European Renal Association (ERA) Congress, Europe’s largest scientific meeting dedicated to #KidneyHealth and care. The #presentation, titled ‘A Novel Podocyte Gene Therapy Enables Pathway to Clinical Translation for the Treatment for Glomerular Diseases,’ demonstrates the development of our novel AAV #GeneTherapy, PS-001, for the delivery of transgenes to the podocyte. This approach demonstrates that transgenes can be efficiently targeted to podocytes, a specialised kidney cell implicated in approximately 60% of kidney diseases, to replace defective genes or mend damage in neighbouring kidney cells. Methods to translate this approach to a clinical setting were also established, paving the way for Purespring’s approach to become the first podocyte-targeted gene therapy to enter clinical development. If you will be at #ERA24, stop by room A7 from 16:57-17:09 CEST to listen to Sam’s presentation or connect with Fredrik Erlandsson, Chief Medical Officer, Alice Brown, Chief Scientific Officer, or Pille Harrison, VP Clinical Development, who will also be attending the #conference. Read the full press release here: https://lnkd.in/eJqvg68q #ERA2024 #Biotech #Innovation #KidneyDisease

The Purespring team, including our Chief Medical Officer, Fredrik Erlandsson, Chief Scientific Officer, Alice Brown, Head of Translational Research, Sam Illingworth, and VP Clinical Development, Pille Harrison, is gearing up for the 61st European Renal Association (ERA) Congress, which kicks off this Thursday in Stockholm, Sweden and online. As Europe’s largest scientific #conference specialising in the field of #nephrology, #ERA24 will once again provide an engaging scientific programme of over 100 sessions, each underscored by this year’s theme: “Rethinking Kidney Health and Transforming Kidney Care.” Sam will present ‘A Novel Gene Therapy to Podocytes Enables Pathway to Clinical Translation for the Treatment of Glomerular Diseases,’ which establishes the potential of AAV #GeneTherapy, with a local route of administration, to deliver transgenes specifically and effectively to the podocyte for the treatment of a range of #KidneyDiseases. The presentation will take place on 24 May from 16:57-17:09 CEST in room A7 – be sure to stop by if you would like to learn more about how our first in class gene therapy approach is laying the foundations to provide a step change in the treatment for patients living with chronic #KidneyDisease. Discover the event’s full agenda here: https://lnkd.in/dznQKtv7

Our colleagues, Tony Bou Kheir, Head of Analytical Development and Quality Control, and Xiangyi Jing, Senior Analytical Scientist, will be in London, UK from today, 22 May, until 24 May to take part in the 5th Annual Gene Therapy Analytical Development Europe #Conference. They will participate in a variety of panels and presentations, including: 🔬Panel Discussion, including insights from Tony and other #LifeSciences industry leaders: ‘Discussing Strategies to Correlate the Outputs of a Potency Matrix Approach to Manage Regulatory Expectations’ from 13:00-14:00BST on 22 May 🧬Presentation of new data from Jing: ‘Utilising HPLC for Analysis of Aggregation & to Enhance Separation Resolution Between Empty, Full & Partial Capsids’ from 12:00-12:30BST on 24 May 🧪Presentation of new data from Tony: ‘Evaluating Best Practice for Analytical Technology Transfer Process to Ensure Smooth Transitions During Upscaling’ from 15:30-16:00BST on 24 May Please stop by if you are also attending, or reach out to Tony or Jing if you want to learn more about our novel AAV #GeneTherapy approach. #Biotech #People #Innovation #KidneyDisease

Tomorrow morning, 22 May, our CEO, Julian Hanak, will give oral evidence to the UK Parliament Science, Innovation and Technology Committee (SITC) in connection with the Committee’s inquiry into commercialising #research. Along with other #LifeSciences and #healthcare industry leaders, Julian will answer questions from 9:30-10:15BST on how the UK government can best support turning the UK’s world-leading scientific research into commercially successful initiatives to maximise potential benefits for health, the economy and society. As a university spin-out founded on pioneering research from world-renowned #renal expert, Professor Moin Saleem, it is encouraging to see that the Government is engaging with science businesses to learn firsthand what businesses need to grow and thrive. Tune in online to watch the session:  https://lnkd.in/e4dcj56c #KidneyDisease #UKBiotech #Growth #GeneTherapy #Innovation

Next week, our CEO, Julian Hanak, and CFO, Sachin Kelkar, will be in San Sebastián, Spain, for Bio€quity Europe 2024, Europe’s largest conference for C-suite and #LifeSciences investors to network, partner and debate critical issues facing the #biotech industry. If you are interested in learning more about our novel #GeneTherapy approach, which has the potential to transform the lives of millions of patients living with chronic kidney diseases, please reach out via the conference’s C-level Partnering platform to set up a meeting with Julian and Sachin. For more information on #BioEquity24: https://lnkd.in/dzunkQc #BioEquityEurope #BioEquity #Conference #KidneyDiseases

This week, Alice Brown, Chief Scientific Officer at Purespring, will be in Baltimore, MD from 7-11 May for the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. ASGCT is one of the most important events in the #GeneTherapy calendar.   Alice will present ‘ Novel AAV Kidney Gene Therapy Enables Podocyte Targeting for the Treatment of Glomerular Disease’ (Poster 1585), which can be viewed in the exhibit hall on Friday, 10 May from 12:00-17:00EDT. The presentation will detail the development of a novel AAV gene therapy approach for direct targeting of a key cell type in the kidney, the podocyte. This unique approach allows us to treat podocytes and mend damage in the neighbouring kidney cells, providing an important modality with the potential to radically transform the treatment of kidney disease.   For the full #ASGCT2024 event programme: https://lnkd.in/gSjPsVn   #KidneyDisease #PosterPresentation #Biotech #Conference

Today is National DNA Day, a day to celebrate the groundbreaking discovery of the double helix in 1953 and the successful completion of the Human Genome Project in 2003. On days like today, we are reminded of the important research and discovery that have resulted in two of the greatest scientific advancements of all time, both of which have accelerated advancements in #GeneTherapy and remain a significant driver of progress and #innovation to date. At Purespring, we have built on these powerful discoveries and are proud to be the first company to treat kidney diseases by directly targeting the podocyte with AAV gene therapy. Learn more about our novel approach here: https://lnkd.in/d8_G__CR #KidneyDisease #DNADay #Biotech #CellAndGeneTherapy